FibroBiologics, Inc., was originally incorporated as a limited liability company under the laws of Texas on April 8, 2021, and then transformed into a Delaware corporation on December 14, 2021. The Company is a clinical-stage cell therapy company focused on developing and commercializing fibroblast-based therapies for patients with chronic diseases with severe unmet medical needs, including degenerative disc disease, multiple sclerosis, wound healing and certain cancers, as well as potential life-prolonging applications including thymus and spleen convulsion reversal.
